These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 1622164)

  • 1. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
    Grosset J; Truffot-Pernot C; Lacroix C; Ji B
    Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
    Lecoeur HF; Truffot-Pernot C; Grosset JH
    Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
    Grosset J; Truffot C; Fermanian J; Lecoeur H
    Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
    Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
    Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
    Jutte PC; Rutgers SR; Van Altena R; Uges DR; Van Horn JR
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1368-72. PubMed ID: 15581207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
    Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
    Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
    Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
    J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
    Ramachandran G; Hemanth Kumar AK; Kannan T; Thangakunam B; Shankar D; Christopher DJ
    Indian J Med Res; 2023; 157(2&3):211-215. PubMed ID: 36861539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
    Dhillon J; Dickinson JM; Sole K; Mitchison DA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.